SCHEMBL5382199

SCHEMBL5382199

O=C1N=NOC1=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5694464 0.69
SCHEMBL50138 0.65
SCHEMBL50281 0.61
SCHEMBL6974171 0.61
SCHEMBL3733761 0.45
SCHEMBL22100500 0.42
Water SCHEMBL28873582 0.34
SCHEMBL29525411 0.33 KDM4E (0.40)
SCHEMBL29525891 0.33 KDM4E (0.40)
SCHEMBL735951 0.30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189747-B2 Method of treating noninflammatory cartilage damage WARNER-LAMBERT COMPANY (US) 2007-03-13 US disclosed
US-7138542-B2 Method of treating tinnitus WARNER LAMBERT COMPANY (US) 2006-11-21 US disclosed
US-20060100281-A1 Method of treating tinnitus DOOLEY DAVID J 2006-05-11 US disclosed
US-7026505-B2 Method of treating tinnitus WARNER-LAMBERT COMPANY (US) 2006-04-11 US disclosed
CN-1625393-A Alpha 2 delta ligands to treat tinnitus WARNER LAMBERT CO (US) 2005-06-08 CN disclosed
EP-1469841-A1 ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS WARNER-LAMBERT COMPANY (US) 2004-10-27 EP disclosed
US-20040097405-A1 Method of treating cartilage damage SCHRIER DENIS (US) 2004-05-20 US disclosed
EP-1400526-A2 ((cyclo)alkyl substituted)- gamma -aminobutyric acid derivatives (=Gaba analogues), their preparation and their use in the treatment of neurological disorders Warner-Lambert Company LLC (US) 2004-03-24 EP disclosed
EP-1045839-B1 NOVEL AMINES AS PHARMACEUTICAL AGENTS WARNER LAMBERT CO (US) 2004-03-03 EP disclosed
US-20030229054-A1 Novel amines as pharmaceutical agents BELLIOTTI THOMAS RICHARD (US) 2003-12-11 US disclosed
US-20030176504-A1 Method of treating tinnitus DOOLEY DAVID JAMES (US) 2003-09-18 US disclosed
US-6620829-B2 Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt WARNER-LAMBERT COMPANY 2003-09-16 US disclosed
WO-2003063845-A1 ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS WARNER-LAMBERT COMPANY LLC (US) 2003-08-07 WO disclosed
US-6521650-B1 Novel gamma aminobutyric acids; treatment of epilepsy, faint-ness attacks, hypokinesia, cranial disorders, neurodegenera-tive disorders, depression, anxiety, panic, pain, neuropatho-logical disorders, inflammation and gastrointestinal damage PFIZER, INC. 2003-02-18 US disclosed
US-20020072533-A1 Method of treating cartilage damage SCHRIER DENIS (US) 2002-06-13 US disclosed
EP-1199072-A2 Method of treating cartilage damage WARNER-LAMBERT COMPANY (US) 2002-04-24 EP disclosed
EP-1045839-A2 NOVEL AMINES AS PHARMACEUTICAL AGENTS Warner-Lambert Company LLC (US) 2000-10-25 EP disclosed
WO-1999031074-A2 ((CYCLO)ALKYL SUBSTITUTED)-.GAMMA.-AMINOBUTYRIC ACID DERIVATIVES (=GABA ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS WARNER-LAMBERT COMPANY (US) 1999-06-24 WO disclosed